T. Rowe Price Associates’s Apogee Therapeutics APGE Stock Holding History

T. Rowe Price Associates’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.5M	Sell	237,210 -905,942	-79%	-$81.6M	﹤0.01%	1014
2026 Q1	$96.2M	Sell	1,143,152 -93,983	-8%	-$6.83M	0.01%	623
2025 Q4	$93.4M	Buy	1,237,135 +486,606	+65%	+$30.6M	0.01%	640
2025 Q3	$29.8M	Sell	750,529 -10,315	-1%	-$394K	﹤0.01%	955
2025 Q2	$33M	Sell	760,844 -61,006	-7%	-$2.32M	﹤0.01%	841
2025 Q1	$30.7M	Sell	821,850 -230,745	-22%	-$8.92M	﹤0.01%	853
2024 Q4	$47.7M	Buy	1,052,595 +294,514	+39%	+$15M	0.01%	774
2024 Q3	$44.5M	Sell	758,081 -10,140	-1%	-$486K	0.01%	788
2024 Q2	$30.2M	Sell	768,221 -402,106	-34%	-$19.5M	﹤0.01%	851
2024 Q1	$77.8M	Buy	1,170,327 +399,646	+52%	+$17.4M	0.01%	606
2023 Q4	$21.5M	Buy	770,681 +154,731	+25%	+$3.1M	﹤0.01%	937
2023 Q3	$13.1M	Buy	+615,950	New	+$13.6M	﹤0.01%	1016

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

T. Rowe Price Associates's APGE Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Apogee Therapeutics (APGE) stake by 79% in Q2 2026, selling an estimated $81.6M and leaving 237,210 shares worth $31.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

T. Rowe Price Associates first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $96.2M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

T. Rowe Price Associates held 237,210 shares of Apogee Therapeutics worth $31.5M as of Q2 2026.
T. Rowe Price Associates sold 905,942 Apogee Therapeutics shares in Q2 2026, an estimated $81.6M.
Apogee Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1014 holding.
T. Rowe Price Associates first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
T. Rowe Price Associates's Apogee Therapeutics position peaked at $96.2M in Q1 2026.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.